GlobeNewswire·Nov 5, 2026, 4:05 PM ET

Caribou Biosciences Reports Third Quarter 2026 Financial Results

Caribou Biosciences reported Q3 2026 GAAP net loss of $26.6 million ($0.25 per share), compared to $27.5 million ($0.30 per share) in Q3 2025.
Third-party licensing revenue for the three months ended September 30, 2026, was $1.6 million, down from $2.2 million in the same period in 2025.
R&D expenses for Q3 2026 totaled $21.3 million, a decrease from $22.4 million in Q3 2025, while G\&A expenses were $7.9 million, down from $9.2 million.
As of September 30, 2026, the company held $94.8 million in cash, cash equivalents, and marketable securities, a reduction from $142.8 million at the end of 2025.
On October 6, 2026, the Board approved a restructuring to explore strategic alternatives, which may include merger, acquisition, or liquidation.
The restructuring includes discontinuing clinical trials for vispa-cel (vispacabtagene regedleucel) and CB-011, along with a substantial workforce reduction.
Caribou cited the challenging financing environment for allogeneic CAR-T cell therapies as the primary driver for halting development of its two lead programs.
No timeline has been set for completing the strategic review, and no further updates will be provided until a course of action is approved or required.
Vispa-cel is an allogeneic anti-CD19 CAR-T therapy with FDA designations including RMAT, Fast Track, and Orphan Drug status for B-NHL.
CB-011 is an allogeneic anti-BCMA CAR-T therapy with FDA designations including RMAT, Fast Track, and Orphan Drug status for r/r MM.